: While many studies show that a variety of immunotherapies can effectuate substantial tumor destruction, much less is known regarding the generation of endogenous anti-tumor responses and their importance to spontaneous tumor formation. Multiple defects in anti-tumor immunity have been described in tumor-bearing hosts, including tumor-specific T cell anergy, tolerance, deletion, and indifference; progressive tumor growth in these cases indicates the absence or failure of tumor defense. In contrast, other work demonstrates that perforin, interferon-gamma (IFN-gamma), interleukin-12 (IL-12), invariant NKT cell, and RAG2 deficient mice develop more tumors in response to chemical carcinogens than wild type littermates. Moreover, aged perforin or fas-fas ligand deficient mice spontaneously form lymphomas, and aged RAG2 and STAT1 doubly deficient mice spontaneously develop carcinomas of the intestine, lung, and breast. Together, these studies illustrate that some endogenous immune responses can modulate tumor formation. Here we show that mice doubly deficient in granulocyte-macrophage colony stimulating factor (GM-CSF) and IFN-gamma or triply deficient in GM-CSF, IFN-gamma, and interleukin-3 (IL-3), to a greater degree, spontaneously develop diverse hematologic and solid tumors in association with infection and inflammatory disease. The unexpected high frequency and broad spectrum of tumors implies that cytokine-mediated regulation of cell growth and immune homeostasis is a critical determinant of cancer susceptibility. However, the mechanisms by which multiple cytokine deficiencies lead to spontaneous tumor development remain to be clarified. In this application, we propose a series of investigations to establish the contributions of compromised immunity, chronic infection, and chronic inflammation to spontaneous tumor formation. These studies should deepen our understanding of protective host responses against tumor development and provide a more detailed framework for designing immunotherapies against incipient and established tumors.
The specific aims of this project are: 1) To characterize anti-tumor immunity in GM-CSF, IL-3, and IFN-gamma deficient mice. 2) To determine the impact of chronic infection and inflammation on tumor development in GM-CSF, IL-3, and IFN-gamma deficient mice. 3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA074886-07
Application #
6623675
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Hecht, Toby T
Project Start
1997-08-01
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
7
Fiscal Year
2003
Total Cost
$235,124
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kuan, Chien-Tsun; Srivastava, Nidhi; McLendon, Roger E et al. (2010) Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 127:598-611
Zarei, Shohreh; Schwenter, Frank; Luy, Patricia et al. (2009) Role of GM-CSF signaling in cell-based tumor immunization. Blood 113:6658-68
Dranoff, Glenn (2005) CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 23:662-4
Katsumoto, Tamiko R; Duda, Jennifer; Kim, Andrew et al. (2005) Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. J Exp Med 201:853-8
Nieuwenhuis, Edward E S; Gillessen, Silke; Scheper, Rik J et al. (2005) CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol 14:250-8
Schmollinger, J C; Dranoff, G (2004) Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9:309-13
Hodi, F Stephen; Mihm, Martin C; Soiffer, Robert J et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-7
Dranoff, Glenn (2003) GM-CSF-secreting melanoma vaccines. Oncogene 22:3188-92
Soiffer, Robert; Hodi, F Stephen; Haluska, Frank et al. (2003) Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343-50
Mollick, Joseph A; Hodi, F Stephen; Soiffer, Robert J et al. (2003) MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 3:3

Showing the most recent 10 out of 28 publications